AZN - Ticker AI Digest

AstraZeneca PLC 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (AZN) 1
AZN 06:01
AstraZeneca PLC
AZN new Head of Investor Relations Joris Silon
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 2
AZN 06:06
AstraZeneca PLC
Subcutaneous Saphnelo approved in EU
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZenecas Saphnelo (anifrolumab) has been approved in the European Union (EU) for subcutaneous self-administration via a pre-filled pen for adult patients with systemic lupus erythematosus (SLE). This approval is based on positive results from the Phase III TULIP-SC trial, which demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to placebo. The subcutaneous option offers patients a more convenient and flexible treatment method, potentially reaching a broader patient population. SLE is a debilitating autoimmune disease affecting over 3.4 million people globally, primarily women, with significant health risks and unmet treatment needs. The approval marks a significant advancement in lupus care, reducing reliance on oral corticosteroids and improving treatment accessibility. Saphnelo is also under regulatory review for subcutaneous administration in other countries, including the US and Japan, and continues to be evaluated in additional autoimmune diseases. This development aligns with AstraZenecas commitment to improving respiratory and immunology care through innovative treatments.
AZN 06:01
AstraZeneca PLC
Enhertu approved in US for 1L HER2+ metastatic BC
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZeneca and Daiichi Sankyos Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the US as a first-line treatment for patients with HER2-positive metastatic breast cancer. This approval is based on the results of the DESTINY-Breast09 Phase III trial, which demonstrated a 44% reduction in the risk of disease progression or death compared to the previous standard of care (THP), with a median progression-free survival (PFS) of over three years. This marks the first new treatment in a decade for this patient population and is expected to become a new standard of care. The approval follows Priority Review and Breakthrough Therapy Designation by the FDA, and the treatment is also under review in other countries through Project Orbis. Financial implications include a $150 million milestone payment from AstraZeneca to Daiichi Sankyo. Enhertu is a HER2-directed antibody-drug conjugate (ADC) jointly developed and commercialized by both companies, with a comprehensive global clinical development program ongoing across multiple HER2-targetable cancers.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 2
AZN 10:01
AstraZeneca PLC
Director/PDMR Shareholding
AZN 10:01
AstraZeneca PLC
Director/PDMR Shareholding
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 1
AZN 06:31
AstraZeneca PLC
Enhertu granted BTD for post-neoadjuvant early BC
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZeneca and Daiichi Sankyos Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) by the U.S. FDA for post-neoadjuvant treatment in adult patients with HER2-positive early breast cancer who have residual invasive disease and a high risk of recurrence. This marks the tenth BTD for Enhertu, based on positive results from the DESTINY-Breast05 Phase III trial, which demonstrated significant clinical benefit over the current standard of care, trastuzumab emtansine (T-DM1). The trial enrolled 1,635 patients globally and showed that Enhertu may reduce the risk of invasive disease recurrence, potentially improving long-term outcomes for patients.
Breast cancer, particularly HER2-positive cases, remains a significant global health challenge, with approximately one in five breast cancers classified as HER2-positive. Despite advances, many patients with residual disease after neoadjuvant treatment face a high risk of recurrence and progression to metastatic disease, which significantly worsens survival rates. Enhertu, a HER2-directed antibody-drug conjugate (ADC), has already been approved in multiple countries for various breast cancer indications, including metastatic HER2-positive, HER2-low, and HER2-ultralow breast cancers.
This BTD underscores Enhertus potential to become a critical treatment option in the post-neoadjuvant setting, addressing a significant unmet medical need. AstraZeneca and Daiichi Sankyo continue to expand Enhertus clinical development program across multiple HER2-targetable cancers, aiming to improve outcomes for patients with breast cancer and other malignancies. The collaboration between the two companies remains focused on advancing innovative therapies to combat cancer and improve patient survival.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
AZN 06:01
AstraZeneca PLC
Update on LATIFY Phase III trial of ceralasertib
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 8
AZN 06:01
AstraZeneca PLC
AZN new Head of Investor Relations Joris Silon
AZN 14:01
AstraZeneca PLC
Total Voting Rights
AZN 10:01
AstraZeneca PLC
Director/PDMR Shareholding
AZN 06:31
AstraZeneca PLC
Enhertu granted BTD for post-neoadjuvant early BC
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZeneca and Daiichi Sankyos Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) by the U.S. FDA for post-neoadjuvant treatment in adult patients with HER2-positive early breast cancer who have residual invasive disease and a high risk of recurrence. This marks the tenth BTD for Enhertu, based on positive results from the DESTINY-Breast05 Phase III trial, which demonstrated significant clinical benefit over the current standard of care, trastuzumab emtansine (T-DM1). The trial enrolled 1,635 patients globally and showed that Enhertu may reduce the risk of invasive disease recurrence, potentially improving long-term outcomes for patients.
Breast cancer, particularly HER2-positive cases, remains a significant global health challenge, with approximately one in five breast cancers classified as HER2-positive. Despite advances, many patients with residual disease after neoadjuvant treatment face a high risk of recurrence and progression to metastatic disease, which significantly worsens survival rates. Enhertu, a HER2-directed antibody-drug conjugate (ADC), has already been approved in multiple countries for various breast cancer indications, including metastatic HER2-positive, HER2-low, and HER2-ultralow breast cancers.
This BTD underscores Enhertus potential to become a critical treatment option in the post-neoadjuvant setting, addressing a significant unmet medical need. AstraZeneca and Daiichi Sankyo continue to expand Enhertus clinical development program across multiple HER2-targetable cancers, aiming to improve outcomes for patients with breast cancer and other malignancies. The collaboration between the two companies remains focused on advancing innovative therapies to combat cancer and improve patient survival.
AZN 06:01
AstraZeneca PLC
Update on LATIFY Phase III trial of ceralasertib
AZN 10:01
AstraZeneca PLC
Director/PDMR Shareholding
AZN 06:06
AstraZeneca PLC
Subcutaneous Saphnelo approved in EU
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZenecas Saphnelo (anifrolumab) has been approved in the European Union (EU) for subcutaneous self-administration via a pre-filled pen for adult patients with systemic lupus erythematosus (SLE). This approval is based on positive results from the Phase III TULIP-SC trial, which demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to placebo. The subcutaneous option offers patients a more convenient and flexible treatment method, potentially reaching a broader patient population. SLE is a debilitating autoimmune disease affecting over 3.4 million people globally, primarily women, with significant health risks and unmet treatment needs. The approval marks a significant advancement in lupus care, reducing reliance on oral corticosteroids and improving treatment accessibility. Saphnelo is also under regulatory review for subcutaneous administration in other countries, including the US and Japan, and continues to be evaluated in additional autoimmune diseases. This development aligns with AstraZenecas commitment to improving respiratory and immunology care through innovative treatments.
AZN 06:01
AstraZeneca PLC
Enhertu approved in US for 1L HER2+ metastatic BC
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZeneca and Daiichi Sankyos Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the US as a first-line treatment for patients with HER2-positive metastatic breast cancer. This approval is based on the results of the DESTINY-Breast09 Phase III trial, which demonstrated a 44% reduction in the risk of disease progression or death compared to the previous standard of care (THP), with a median progression-free survival (PFS) of over three years. This marks the first new treatment in a decade for this patient population and is expected to become a new standard of care. The approval follows Priority Review and Breakthrough Therapy Designation by the FDA, and the treatment is also under review in other countries through Project Orbis. Financial implications include a $150 million milestone payment from AstraZeneca to Daiichi Sankyo. Enhertu is a HER2-directed antibody-drug conjugate (ADC) jointly developed and commercialized by both companies, with a comprehensive global clinical development program ongoing across multiple HER2-targetable cancers.

AI Crunch

Single-Ticker AI Crunch
AZN signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for AstraZeneca PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full AZN AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for AZN on 2026-01-08.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
231353303040
Enterprise Value
188046885670
Public Float
99.52
Broker Target
16212.231
Shares Out
1550833276
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB0009895292
Market
LSE - MAIN MARKET
Sector
Health Care
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
2.36
Ex Divi
2026-02-19
Earnings Date
2026-02-05
Net Debt
23911000000.0
Cash
5711000000.0
EPS
4.89
Net Income
10225000000.0
Revenue
58739000000.0
Enterprise Value
188046885670
Trailing PE
30.5072
Forward PE
19.2308
Price Sales TTM
3.9387
Price Book MRQ
6.2017
EV Revenue
5.6989
EV EBITDA
17.1614

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
4.9735
Institutions As Of
2025-12-04
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
5
Sale Director Dealing
2
Purchase TR1
3
Sale TR1
3
Broker Coverage Rows
38
Institution Holders Tracked
1
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit AZN.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2026-01-08 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
AstraZeneca PLC has fresh news flow feeding the chart narrative.
06:01 Today's Catalyst AZN new Head of Investor Relations Joris Silon
AI Charts Studio
AZN Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-01-08 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 2.45%
RSI Gauge
Price Change
AI Forecast